Earnings Call Summary | Ekso Bionics Holdings, Inc.(EKSO.US) Q1 2024 Earnings Conference
Earnings Call Summary | Ekso Bionics Holdings, Inc.(EKSO.US) Q1 2024 Earnings Conference
The following is a summary of the Ekso Bionics Holdings, Inc. (EKSO) Q1 2024 Earnings Call Transcript:
以下是 Ekso Bionics Holdings, Inc. (EKSO) 2024 年第一季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Ekso Bionics reported a Q1 2024 revenue of $3.8 million, a slight decrease from Q1 2023's revenue of $4.1 million.
The company saw an increase in gross margin to 52% in Q1 2024, up from 49% in Q1 2023, primarily due to the lower EksoHealth device and service costs.
They also successfully reduced their operating expenses by 19%, falling to $5.2 million in Q1 2024 from $6.4 million in Q1 2023, largely due to decreased administrative expenses.
The net loss in Q1 2024 was lower with a loss of $3.4 million ($0.20 per share) compared to a loss of $4.4 million ($0.33 per share) in Q1 2023.
Ekso Bionics報告稱,2024年第一季度收入爲380萬美元,較2023年第一季度的410萬美元收入略有下降。
該公司的毛利率從2023年第一季度的49%增長到2024年第一季度的52%,這主要是由於EksoHealth設備和服務成本的降低。
他們還成功地將運營支出減少了19%,從2023年第一季度的640萬美元降至2024年第一季度的520萬美元,這主要是由於管理費用減少。
2024年第一季度的淨虧損較低,虧損340萬美元(每股虧損0.20美元),而2023年第一季度的虧損爲440萬美元(每股虧損0.33美元)。
Business Progress:
業務進展:
Ekso Bionics sold a total of 29 EksoHealth devices in Q1 2024, influenced mildly by the onset of seasonality.
The final payment determination for Medicare reimbursement for the company's Indego Personal device has been confirmed, allowing them to target clinical, home, and community settings as well as potential Medicare and Medicaid-covered individuals with spinal cord injuries.
Ekso is planning to expand by establishing more certified training centers all over the US.
The interest in Ekso Bionics in the international market, especially in the EMEA region, is steadily rising.
The sales in Ekso's Industrial segment, EksoWorks, saw a remarkable increase of nearly 60% in Q1 2024 from Q1 2023.
With the established reimbursement pricing for the Ekso Indego Personal by CMS, Ekso Bionics looks forward to driving growth.
受季節性來臨的溫和影響,Ekso Bionics在2024年第一季度共售出了29臺EksoHealth設備。
該公司Indego Personal設備醫療保險報銷的最終付款決定已得到確認,這使他們能夠將臨床、家庭和社區環境以及潛在的Medicare和Medicaid承保的脊髓損傷患者作爲目標。
Ekso計劃通過在美國各地建立更多認證培訓中心來擴大規模。
國際市場,尤其是歐洲、中東和非洲地區對Ekso Bionics的興趣正在穩步上升。
埃克索工業板塊EksoWorks的銷售額在2024年第一季度比2023年第一季度顯著增長了近60%。
隨着CMS對Ekso Indego Personal的既定報銷定價,Ekso Bionics有望推動增長。
More details: Ekso Bionics Holdings, Inc. IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。